Physician profile

Alaa Mansour

Family Medicine · Eastpointe, MI

NPI 1902896608

$8,277.53

in general payments reported to CMS, 2019-2025

46 companies · $1,151 in 2025

The $1,151 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,671.80

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $1,415.72 2019-2025 Repatha, Otezla, Repatha
Lilly USA, LLC $1,054.66 2019-2025 Mounjaro, Zepbound, Trulicity
Novo Nordisk INC $816.84 2019-2025 Ozempic, Rybelsus
Astrazeneca Pharmaceuticals LP $645.48 2020-2025 Airsupra, Breztri
Pfizer INC. $628.22 2019-2025
Boehringer Ingelheim Pharmaceuticals, INC. $369.28 2019-2024 Jardiance
Glaxosmithkline, LLC. $249.11 2019-2025 Trelegy Ellipta, Arexvy
Abbott Laboratories $234.79 2021-2025 Freestyle Libre 3
Abbvie INC. $222.14 2021-2023
Bayer Healthcare Pharmaceuticals INC. $216.54 2021-2022
Stryker Corporation $173.48 2024 Infinity, Ortholoc 3di
Phathom Pharmaceuticals, INC. $163.49 2024 Voquezna
Aroa Biosurgery Incorporated $134.19 2024
Horizon Therapeutics Plc $125.08 2021
Acumed LLC $125.03 2023 Acumed, Osteomed
Show all 46 companies
CompanyGeneral paymentsYearsTop products
Corcept Therapeutics $124.99 2025 Korlym
Treace Medical Concepts, INC. $117.95 2023
Otsuka America Pharmaceutical, INC. $107.10 2022
Dexcom, INC. $104.82 2021-2025 Dexcom G6 Transmitter
Genzyme Corporation $104.21 2022
Janssen Pharmaceuticals, INC $100.06 2019-2022
Sanofi-Aventis U.S. LLC $96.05 2020-2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $92.23 2022-2025 Xifaxan
Exact Sciences Corporation $90.20 2025 Cologuard Collection Kit
Zimmer Biomet Holdings, INC. $90.05 2022
Astellas Pharma US INC $74.49 2020-2025 Veozah
Sunovion Pharmaceuticals INC. $73.03 2019
Ascend Therapeutics US, LLC $59.94 2021
Depuy Synthes Sales INC. $54.59 2022
Biohaven Pharmaceutical Holding Company LTD. $53.26 2022
Biohaven Pharmaceuticals, INC. $49.96 2020-2021
Global Blood Therapeutics, INC. $42.56 2021-2022
Novartis Pharmaceuticals Corporation $34.38 2022-2024
Mannkind Corporation $27.88 2019
Kiniksa Pharmaceuticals, LTD. $26.50 2023 Arcalyst
Boston Scientific Corporation $24.46 2023 Eluvia
Amarin Pharma, INC. $24.33 2021
W. L. Gore & Associates, INC. $18.45 2020
Mimedx Group, INC. $16.87 2024
Ultragenyx Pharmaceutical INC. $16.18 2021
Verona Pharma, INC. $14.62 2025 Ohtuvayre
Hikma Pharmaceuticals USA $14.39 2019
Photocure INC $13.98 2021
Metuchen Pharmaceuticals $13.69 2019
Teva Pharmaceuticals USA, INC. $11.14 2020
Arbor Pharmaceuticals, INC. $11.12 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Alaa Mansour

$8,277.53

in general payments reported 2019-2025

Years
2019-2025
Top company
Amgen INC.
Context
The $1,151 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/132124/alaa-mansour

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.